Cardiology

In his recent presentation, Dr. Sperling spoke of how a greater focus needed to be made on the implementation of cardiovascular care strategies, as well as better utilization of health system approaches.

A trial comparing 3 eating patterns suggests a healthy dietary approach could lower cardiovascular risk factors among pediatric patients considered to be overweight or obese.

No significant difference in mortality or stroke at 30 days or 1 year was seen in patients who underwent TAVR for bicuspid or tricuspid aortic stenosis.

Manesh Patel, MD, kicks off his first podcast by discussing HFpEF findings in EMPEROR-Preserved, the GUIDE-HF trial and more with his Duke colleague.

On September 20, Abbott announced the FDA had approved their Portico with FlexNav TAVR system for patients with symptomatic, severe aortic stenosis based on results of the PORTICO IDE Trial.

Released on September 20, the latest scientific statement from the AHA outlines potential strategies, including lifestyle modifications, pharmacologic therapies, and weight loss surgery, for the prevention and treatment of obesity hypertension.

Professor Kausik Ray provides perspective on the most recent cardiovascular disease prevention guidelines debuted by the European Society of Cardiology at ESC Congress 2021.

The potential number of adults projected to be newly eligible for treatment had a range from 643,161 (LVEF, 41% - 50%) to 1,838,756 (LVEF, 41% - 60%).

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Presented at HFSA 2021, results of REDWOOD-HCM provide insight into the effects of the oral selective cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy.

An expert considers the buildup of cardiovascular and cardiometabolic innovation, and the role of regulatory delays in it.

Silvio Inzucchi, MD, discusses his presentation on the role of diabetes medications, including SGLT2 inhibitors and GLP-1 RAs, in stroke prevention from TMIOA's 5th Heart in Diabetes conference.

An overlooked aspect of an under-discussed condition, Andrea Dunaif, MD, provided an overview of the cardiovascular risk seen among women with polycystic ovary syndrome.

How inclisiran, bempedoic acid, and other investigative therapies may contribute to cardiometabolic disease management.

The cardiologist discusses the lagging nature of US health care authorization and recommendation for already proven agents in cardiovascular risk reduction.

Research shows direct associations between unmanaged, severe OSA and cardiovascular event incidence. An expert reviews mechanisms and cross-sectional studies.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Our latest case report from Brady Pregerson, MD, features an elderly woman with a history of diabetes experiencing sweats, light-headedness, nausea, and SOB. Can you determine the correct diagnosis?

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

A look at how European experts have shaped risk assessment through demographic-centric algorithms.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.